Results 231 to 240 of about 19,745 (243)
Some of the next articles are maybe not open access.
Biotechnology Progress, 2018
Production of knob and hole dual light chain bispecific antibodies poses several unique challenges for development of a feasible industrial scale manufacturing process. We developed an efficient process for the assembly and purification of knob and hole dual light chain bispecific antibodies.
Glen Giese +3 more
openaire +3 more sources
Production of knob and hole dual light chain bispecific antibodies poses several unique challenges for development of a feasible industrial scale manufacturing process. We developed an efficient process for the assembly and purification of knob and hole dual light chain bispecific antibodies.
Glen Giese +3 more
openaire +3 more sources
Bispecific Antibodies for Cancer Therapy
Immunotherapy, 2009Bispecific antibodies, in contrast to conventional monoclonal antibodies, can bind simultaneously two different antigens. Taking advantage of this virtue, they are mostly designed for immune effector cell redirection to tumors and for radionuclide pretargeting to tumors.
openaire +3 more sources
Producing Bispecific and Bifunctional Antibodies
2004Bispecific antibodies are artificially engineered monoclonal antibodies (MAbs) that consist of two distinct binding sites and are capable of binding two different antigens noncovalently. They can be produced by chemical cross-linkage, genetic engineering, or somatic hybridization.
Mavanur R. Suresh, Dipankar Das
openaire +3 more sources
Bispecific Antibody Therapy in Hemophilia
New England Journal of Medicine, 2017Hemophilia A is the most common severe inherited bleeding disorder in humans. Bleeding occurs as a result of a deficiency or dysfunction of the procoagulant cofactor protein, factor VIII. For the past 50 years, the treatment and prevention of bleeding in hemophilia A has involved the intravenous infusion of plasma-derived or recombinant factor VIII ...
openaire +3 more sources
Bispecific antibodies rise again
Nature Reviews Drug Discovery, 2014Amgen's blinatumomab is setting the stage for a bispecific revival, enabled by new formats that may solve the field's long-standing problems.
openaire +3 more sources
Introduction: bispecific antibodies
Journal of Immunological Methods, 2001George J. Weiner +2 more
openaire +3 more sources
Resistance to Bispecific T-Cell Engagers and Bispecific Antibodies
2019Bispecific antibodies are an emerging novel therapeutic construct used to treat a variety of cancers. These drugs utilize a small fusion protein to link two single-chain antibodies, allowing for simultaneous binding of two different epitopes. Bispecific T-cell engagers (BiTE) are a subset of bispecific antibodies that bind the target antigen on the ...
Stacy Cooper, Patrick A. Brown
openaire +2 more sources
Immunotherapy with bispecific antibodies.
Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie, 1995With rare exceptions, monoclonal antibodies as therapeutic agents for cancer, have had limited anti-tumor effects. Attempts to improve the cytotoxicity of antibodies by using them as guiding agents for immune effector cells, have been developed. Numerous in vitro studies have shown that T lymphocytes can be targeted towards any target cell by using ...
openaire +2 more sources
Bispecific antibodies in myeloma
Hématologie, 2021Sophie Le Grand, Aurore Perrot
openaire +1 more source